This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameMedrogestone
Accession NumberDB09124
TypeSmall Molecule
GroupsApproved
Description

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestin, a synthetic drug with similar effects as progesterone, a hormone involved in the menstrual cycle and pregnancy. As of 2010, it is no longer available in Germany or Austria.

Structure
Thumb
SynonymsNot Available
External IDs AY 62022 / AY-13615 / AY-13615S / AY-62022 / NSC-123018
Product Ingredients Not Available
Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colprone Tab 5mgTablet5 mgOralWyeth Ayerst Canada Inc.1996-10-252001-08-30Canada
Colprone Tab 5mgTablet5 mgOralAyerst Laboratories1969-12-311997-08-15Canada
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII077DN93G5B
CAS number977-79-7
WeightAverage: 340.507
Monoisotopic: 340.24023027
Chemical FormulaC23H32O2
InChI KeyHCFSGRMEEXUOSS-JXEXPEPMSA-N
InChI
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
IUPAC Name
SMILES
[H][[email protected]@]12CC[[email protected]](C)(C(C)=O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])C=C(C)C2=CC(=O)CC[[email protected]]12C
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Medrogestone.Approved
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Medrogestone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Medrogestone.Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medrogestone.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medrogestone.Approved
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone.Approved, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medrogestone.Approved, Investigational
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Medrogestone.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medrogestone.Approved
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Medrogestone.Approved
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medrogestone.Nutraceutical, Vet Approved
Conestat alfaMedrogestone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medrogestone.Approved, Withdrawn
DarexabanThe therapeutic efficacy of Ym150 can be decreased when used in combination with Medrogestone.Investigational
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Medrogestone.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Medrogestone.Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Medrogestone.Approved, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Medrogestone.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Medrogestone.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Medrogestone.Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Medrogestone.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Medrogestone.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Medrogestone.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.Approved, Investigational
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medrogestone.Approved, Vet Approved
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medrogestone.Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medrogestone.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Medrogestone.Withdrawn
FluindioneThe therapeutic efficacy of Fluindione can be decreased when used in combination with Medrogestone.Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Medrogestone.Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Medrogestone.Approved, Investigational
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Medrogestone.Investigational
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Medrogestone.Approved, Investigational
Human C1-esterase inhibitorMedrogestone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
IdraparinuxThe therapeutic efficacy of idraparinux can be decreased when used in combination with Medrogestone.Investigational
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.Approved
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medrogestone.Approved
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medrogestone.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Medrogestone.Experimental
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medrogestone.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Medrogestone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medrogestone.Approved, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medrogestone.Approved
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Medrogestone.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Medrogestone.Approved
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Medrogestone.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Medrogestone.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Medrogestone.Approved
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medrogestone.Approved
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medrogestone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medrogestone.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Medrogestone.Approved, Investigational
UlipristalThe therapeutic efficacy of Medrogestone can be decreased when used in combination with Ulipristal.Approved
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Medrogestone.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Medrogestone.Approved, Investigational, Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesG03FB07 — Medrogestone and estrogenG03DB03 — Medrogestone
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00404 mg/mLALOGPS
logP4.35ALOGPS
logP4.59ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)19.18ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity102.6 m3·mol-1ChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents20-oxosteroids / 3-oxosteroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
SubstituentsProgestogin-skeleton / 20-oxosteroid / Oxosteroid / 3-oxosteroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide / Hydrocarbon derivative
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Drug created on September 23, 2015 10:20 / Updated on September 03, 2017 12:33